ARTICLE | Product Development
Novavax’s COVID-19 vaccine headed into the clinic; data due in July
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 8, 2020 1:11 PM UTC
Updated on Apr 8, 2020 at 10:36 PM UTC
Novavax could have preliminary data as soon as July from a planned first-in-human trial of its COVID-19 vaccine, the company said Wednesday.
Next month, Novavax Inc. (NASDAQ:NVAX) intends to start the Phase I trial of NVX-CoV2373, with about 130 healthy adult subjects receiving the vaccine or placebo. Novavax said the trial is starting weeks ahead of schedule; early safety and immunogenicity results are due two months later...
BCIQ Company Profiles